Are Weight-Loss Injections About to Become Cheaper?
In this article
The GLP-1 World’s 2026 Revolution: The Battle Between Access and Economics
From a biological revolution to essential medicine status: the collapse of global patent walls and a new era in oncological protection.
The lifting of patent protection is critical not only for patients with diabetes and obesity, but also for expanding the potential use of these molecules in areas such as cardiovascular protection and neuro-oncology (brain metastases, etc.).
1. India and China: The March 2026 “Big Bang”
The Asian market has become the front line of the fiercest competition for semaglutide (Ozempic/Wegovy).
- India: As of 20 March 2026, basic patent protection for semaglutide expired. In India, known as the “pharmacy of the world”, giants such as Sun Pharma, Dr. Reddy's and Cipla are counting down to launching their generic versions. Prices are expected to fall by 70% to 90%.
- China: Following the legal battle against Novo Nordisk’s patents, semaglutide patent protection in China ended in March 2026. There are currently more than 17 biosimilar candidates in phase-3 development in China. This means an enormous increase in capacity for the global supply chain.
2. Türkiye: A Critical Threshold at the End of 2026
Semaglutide’s patent term is expected to expire by the end of 2026 in 10 key countries, including Türkiye.
- Foreign currency-related difficulties in accessing medicines and supply problems in our country have increased the domestic pharmaceutical industry’s appetite for this area.
- From the second half of 2026, licensing processes for biosimilar/generic GLP-1 products in Türkiye are also expected to accelerate, with more affordable options emerging for reimbursement lists.
3. The United States and Europe: A Two-Stage Transition
The strategy in the Western world is a little more complex. Originator manufacturers (Novo Nordisk and Eli Lilly) are trying to extend the protection period through “secondary patents”.
- Liraglutide (Victoza/Saxenda): Patents for this molecule expired in 2024-2025. By 2026, companies such as Teva and Hikma had expanded the availability of the first generic GLP-1 products in the US market.
- Semaglutide: Although the basic compound patent remains in force until 2031-2032 in the US and EU, limited competition is expected to begin in 2026-2027 through agreements covering certain dosages.
4. Russia, Brazil and Canada: Legal Battles
- Russia: The government resorted to “compulsory licensing” for semaglutide. Local companies such as Geropharm have begun producing their own versions (Semavik, etc.).
- Brazil: The market opened fully for semaglutide after a request for a patent extension was rejected in March 2026. With prices falling, its inclusion in the public health system (SUS) is under discussion.
- Canada: With data exclusivity expiring in January 2026, Canada became one of the first G7 countries to begin accepting generic applications.
Patent Status Summary (March 2026)
| Country/Region | Semaglutide Patent Status | Expected Impact |
|---|---|---|
| India | Expired (March 20) | Price reductions of up to 90%, enormous export potential. |
| China | Expired (March 20) | Market entry of 17+ domestic biosimilars. |
| Türkiye | Expires at the End of 2026 | Expectations of domestic production and easier access. |
| US | 2031-2042 (Protected) | Liraglutide is generic; semaglutide prices remain high. |
| Russia | Compulsory Licensing Active | Domestic production without recognising patents. |
| Canada | Expired (January) | Generic approvals awaited. |
Sources
1. Journal of Medical Economics. "The Impact of GLP-1 Patent Expirations on Global Health Systems." 2026.
2. World Intellectual Property Organization (WIPO). "Pharmaceutical Patent Landscapes: GLP-1 Agonists." March 2026 Update.
3. Pharmaceutical Technology. "Generics Boom in Emerging Markets: The Case of Semaglutide." 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.
The “patent revolution” we are witnessing in the GLP-1 world in 2026 has once again proved that medicine is not only a biological discipline but also an economic one. Expensive drugs ceasing to be an “elite” treatment and becoming part of broad public health policies heralds a new era in oncological and metabolic management.
Particularly in neuro-oncology, data such as the mortality benefit provided by GLP-1 receptor activation in diabetic patients with brain metastases have shown that the potential of these molecules is not limited to blood glucose regulation. Economic accessibility is becoming the strongest supporter of clinical success. For precise oncological support and metabolic management, following this economic transformation alongside clinical guidelines will be one of the most important components of future medical practice.